DELAHAYE, F., V.H. CHU, J. ALTCLAS, B. BARSIC, A. DELAHAYE, Tomáš FREIBERGER, D.L. GORDON, M.M. HANNAN, B. HOEN, S.S. KANJ, T. LEJKO-ZUPANC, C.A. MESTRES, O. PACHIRAT, P. PAPPAS, C. LAMAS, C. SELTON-SUTY, R. TAN, P. TATTEVIN a A. WANG. One-year outcome following biological or mechanical valve replacement for infective endocarditis. International Journal of Cardiology. Clare (Ireland): Elsevier Ireland Ltd., 2015, roč. 178, January, s. 117-123. ISSN 0167-5273. Dostupné z: https://dx.doi.org/10.1016/j.ijcard.2014.10.125.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název One-year outcome following biological or mechanical valve replacement for infective endocarditis
Autoři DELAHAYE, F. (250 Francie), V.H. CHU (840 Spojené státy), J. ALTCLAS (32 Argentina), B. BARSIC (191 Chorvatsko), A. DELAHAYE (250 Francie), Tomáš FREIBERGER (203 Česká republika, garant, domácí), D.L. GORDON (36 Austrálie), M.M. HANNAN (372 Irsko), B. HOEN (250 Francie), S.S. KANJ (422 Libanon), T. LEJKO-ZUPANC (705 Slovinsko), C.A. MESTRES (724 Španělsko), O. PACHIRAT (764 Thajsko), P. PAPPAS (840 Spojené státy), C. LAMAS (76 Brazílie), C. SELTON-SUTY (250 Francie), R. TAN (36 Austrálie), P. TATTEVIN (250 Francie) a A. WANG (840 Spojené státy).
Vydání International Journal of Cardiology, Clare (Ireland), Elsevier Ireland Ltd. 2015, 0167-5273.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 30201 Cardiac and Cardiovascular systems
Stát vydavatele Irsko
Utajení není předmětem státního či obchodního tajemství
WWW URL
Impakt faktor Impact factor: 4.638
Kód RIV RIV/00216224:14740/15:00082466
Organizační jednotka Středoevropský technologický institut
Doi http://dx.doi.org/10.1016/j.ijcard.2014.10.125
UT WoS 000345697300033
Klíčová slova anglicky Infective endocarditis; Surgery; Valve prosthesis
Štítky rivok
Příznaky Mezinárodní význam, Recenzováno
Změnil Změnila: Mgr. Eva Špillingová, učo 110713. Změněno: 22. 3. 2016 11:11.
Anotace
Background: Nearly half of patients require cardiac surgery during the acute phase of infective endocarditis (IE). We describe the characteristics of patients according to the type of valve replacement (mechanical or biological), and examine whether the type of prosthesis was associated with in-hospital and 1-year mortality. Methods and results: Among 5591 patients included in the International Collaboration on Endocarditis Prospective Cohort Study, 1467 patients with definite IE were operated on during the active phase and had a biological (37%) or mechanical (63%) valve replacement. Patients who received bioprostheses were older (62 vs 54 years), more often had a history of cancer (9% vs 6%), and had moderate or severe renal disease (9% vs 4%); proportion of health care-associated IE was higher (26% vs 17%); intracardiac abscesses were more frequent (30% vs 23%). In-hospital and 1-year death rates were higher in the bioprosthesis group, 20.5% vs 14.0% (p = 0.0009) and 25.3% vs 16.6% (p < .0001), respectively. In multivariable analysis, mechanical prostheses were less commonly implanted in older patients (odds ratio: 0.64 for every 10 years), and in patients with a history of cancer (0.72), but were more commonly implanted in mitral position (1.60). Bioprosthesis was independently associated with 1-year mortality (hazard ratio: 1.298). Conclusions: Patients with IE who receive a biological valve replacement have significant differences in clinical characteristics compared to patients who receive a mechanical prosthesis. Biological valve replacement is independently associated with a higher in-hospital and 1-year mortality, a result which is possibly related to patient characteristics rather than valve dysfunction. (C) 2014 Elsevier Ireland Ltd. All rights reserved.
VytisknoutZobrazeno: 2. 5. 2024 17:45